Policy
Moderna Stock Eyes Record Year as Analyst Dismisses China AI Lead
Moderna shares head toward a record annual gain as investors await crucial Phase 3 melanoma trial data, while a senior analyst pushes back on claims regarding China's competitive standing in AI-driven drug development. For traders, the upcoming clinical catalysts highlight the divergence between speculative headlines and actionable trial outcomes.
oil gasutilitiesclean energy
If clinical trial data from the Moderna and Merck pipeline meets expectations, watch because detailed Phase 3 efficacy figures serve as the primary fundamental catalyst for the equity.
